Vivek Nimgaonkar retweeted
Exciting news! Valar Labs is proud to announce #Vesta, the first histology-based test for predicting response to #BCG in #BladderCancer.
Press Release: bit.ly/44q09CF
Vivek Nimgaonkar retweeted
1st #bladdercancer drug targeting a cancer-driving gene #mutation hasn't been given often to patients despite showing efficacy. The study in @JAMAOnc led by @Ron_cology, @EricaCarpenter1, Vivek Nimgaonkar, & @RhubbBstat conveys essential use:
spr.ly/6010zJSiM.
Vivek Nimgaonkar retweeted
We are excited to announce our $4m seed round led by @a16z to reimagine cancer treatment decisions with artificial intelligence!
valarlabs.medium.com/valar-l…
Vivek Nimgaonkar retweeted
Patients with #COVID19 admitted to the ICU were 10X more likely to have a significant heart arrhythmias than others hospitalized, from a series of 700 patients @PennMedicine
heartrhythmjournal.com/artic… @hrs_journal by @anjbhatla and colleagues
T27 presenting the Artificial Baroreceptor at the Rothberg Catalyzer #CatalyzeratPenn Thx to @FSilvestryMD for inspiring a Cards interest in penn med students!
Team Sleep Easy ready to get some shut eye at the late (early?) hour of 4:08am #CatalyzeratPenn
14hrs after starting T27 has the artificial baroreceptor successfully measuring pressures in a model, proof of concept, hemodynamic system #CatalyzeratPenn
No sleep ahead for team Sleep Easy! Popping in at the team check-in before the night ahead #CatalyzeratPenn
T27 Sleep Easy beginning to pull together sensor functionality for the artificial baroreceptor @CatalyzerAtPenn
Team27 Sleep Easy is up and ready to go for the Rothberg Catalyzer #CatalyzeratPenn #RothbergCatalyzeratPenn











